Background The lower airway microbiota in patients with chronic obstructive pulmonary disease (COPD) are likely altered compared with the microbiota in healthy individuals. Information on how the ...

Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma’s new ch… ...